Mansour Mohamadzadeh

Mansour Mohamadzadeh, PhD

Director, Center For Inflammation & Mucosal Immunology; Professor

Department: Department of Infectious Diseases & Immunology
Business Phone: (352) 294-4117
Business Email: m.zadeh@ufl.edu

About Mansour Mohamadzadeh

Dr. Mohamadzadeh is an immunologist with expertise in the fields of inflammation, systemic/mucosal immunology, infection, and vaccine delivery. He is also experienced in working with various therapeutic approaches that focus on the role of innate immune cells, particularly dendritic cells, and how these cells determine the fate of virgin T and B cells toward various T and B cell subset activation in steady state, infection, and auto inflammatory diseases, including IBD and colon cancer. Additionally, his focus is currently centered on an oral targeted vaccine that not only induces intestinal but also systemic immune responses against pathogen challenge.

Accomplishments

Honorary Member
2013-Current · Phi Zeta Society, Upsilon Chapter
Member
2012-Current · KL2 Multidisciplinary Advisory Committee, CTSI, University of Florida
Member
2012-Current · Society of Mucosal Immunology
Member
2011-Current · Cancer Genetics Institute, UF
Member
2011-Current · Emerging Pathogens Institute (EPI), University of Florida
Associate Editor
2011-Current · J. Immunotherapy
Associate Editor
2011-Current · Frontiers in Immunology
Member
2009-2012 · IACUC committee, NW University
Associate Editor
2007-2011 · Journal of Immunology
Member
2005-Current · American Society for Microbiology
Grants Merit Review
2003-Current · National Institute of Health (NIH)
Member
1998-2020 · American Association of Immunologists (AAI)
Member
1996-2020 · American Association for the Advancement of Science (AAAS)

Research Profile

Dr. Mohamadzadeh is an immunologist with over 25 years of expertise in the fields of inflammation, systemic/mucosal immunology, infection, and vaccine delivery. He is also experienced in working with various therapeutic approaches that focus on the role of innate immune cells–particularly dendritic cells, and how these cells determine the activation and differentiation of T lymphocytes, including T cells, such as TH17 or extrathymic regulatory T cells (Tregs) in steady state, during infection, and throughout autoinflammatory intestinal disorders such as inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC). In his opinion, understanding the molecular mechanisms underlying intestinal immune regulation is most effective when host interactions with intestinal bacterial species and their bacterial products are fully understood, and when the critical molecules that culminate in inflammation or anti-inflammatory responses are identified. Thus, his research is firmly centered on the specifics of beneficial gut microbes, their unique properties, and their role in the induction of stimulatory or regulatory signals in innate cells and T lymphocytes, contributing directly to further proinflammation or regulation of inflammatory diseases (IBD, NEC). Pragmatically, his research is tightly entwined with generating novel therapies for intestinal disorders (e.g. NEC) using beneficial bacteria such as P. UF1 to significantly regulate induced pathogenic inflammation in sufferers who urgently need it. Furthermore, his team also established a novel targeted vaccine platform, dual route vaccine, to mobilize protective humoral immunity against infectious agents, including botulinum neurotoxin A complex (BoNT/A), in animals and man. The same dual route vaccine platform is currently optimized to elucidate the efficacy of probiotic bacterium, P. UF1, expressing PD-1 molecule to generate neutralizing antibody against PD-1 to inhibit T cell exhaustion and to protect against melanoma cancer. This elegant and less costly approach will be further developed and tested in higher animals, including dogs affected by melanoma and hopefully in phase 1 clinical trial in man in the near future.

Publications

2019 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2019 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2016 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2015 Trends in Molecular Medicine
2013 Current Pharmaceutical Biotechnology

Grants

Jul 2019 ACTIVE
Novel oral targeted breast carcinoma vaccine
FL BREAST CANCER FOU · Principal Investigator
Jun 2019 ACTIVE
OR-DRPD-ROF2019: Prenatal stress, the gut microbiota and infant susceptibility to malaria
UF RESEARCH ·
Jan 2019 ACTIVE
Gut dysbiosis and tryptophan metabolism in lupus
NATL INST OF HLTH NIAID ·
May 2016 ACTIVE
Bacterial surface layer specific immune protection gut microbial infection
NATL INST OF HLTH NIDDK · Principal Investigator
Jan 2016 – Dec 2018
Gut dysbiosis induces iupus
NATL INST OF HLTH NIAID ·
Feb 2015 ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
UF HEALTH SHANDS HOSPITAL · Project Manager
Jul 2014 – Dec 2018
The Role of the Intestinal Microbiota in the Development
FL BREAST CANCER FOU · Principal Investigator
Sep 2011 – Jul 2018
Novel multivalent vaccine for anthrax and botulinum
NATL INST OF HLTH NIAID · Principal Investigator
Jul 2007 – Aug 2016
Clinical and Translational Science Institute
UF RESEARCH FOU · Project Manager

Patents

Issued February 2013
Dendritic Cell Binding Proteins and Uses Thereof
#8,372,409
Published October 2016
Lipoteichoic Acid From Lactobacilli as a Potent Immune Stimulatory Adjuvant for Vaccine Development
#US-2017-0035880-A1
Published November 2017
Propionibacterium Freudenreichii as a Probiotic for Infants
#US-2018-0199611-A1

Education

Doctor of Philosophy in Cellular & Molecular Immunology
1991 · Johannes Gutenberg University
Master of Science in Cellular & Molecular Immunology
1989 · Johannes Gutenberg University
Bachelor of Science in Cellular & Molecular Biology
1986 · Johannes Gutenberg University/Germany

Contact Details

Phones:
Business:
(352) 294-4117
Emails:
Business:
m.zadeh@ufl.edu